On November 13, 2017, the U.S. Food and Drug Administration (FDA) approved Abilify MyCite (aripiprazole tablets with sensor), the first drug in the United States with a digital ingestion tracking system. Abilify MyCite is the tablet form of the antipsychotic aripiprazole manufactured with an embedded ingestible sensor. The sensor records that the medication was taken, and communicates that information to a mobile application, via a wearable patch. Abilify MyCite is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in . . .
News Report |